Skip to main navigation
Skip to search
Skip to main content
University of Kentucky Home
LOGIN & Help
Home
Research units
Researchers
Projects & Grants
Research Output
Facilities & Equipment
Honors & Awards
Activities
Search by expertise, name or affiliation
23-NHL-31-CB-PMC: CB-10A, A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Yalniz, Fevzi
(PI)
Markey Cancer Center / Cancer Research Priority Initiative
Overview
Grants and Contracts Details
Status
Active
Effective start/end date
9/8/23
→
9/8/25
Funding
Caribou Biosciences Incorporated:
$75,265.00
View all
View less